TY - JOUR
T1 - Normal and malignant megakaryopoiesis.
AU - Wen, Qiang
AU - Goldenson, Benjamin
AU - Crispino, John D.
PY - 2011
Y1 - 2011
N2 - Megakaryopoiesis is the process by which bone marrow progenitor cells develop into mature megakaryocytes (MKs), which in turn produce platelets required for normal haemostasis. Over the past decade, molecular mechanisms that contribute to MK development and differentiation have begun to be elucidated. In this review, we provide an overview of megakaryopoiesis and summarise the latest developments in this field. Specially, we focus on polyploidisation, a unique form of the cell cycle that allows MKs to increase their DNA content, and the genes that regulate this process. In addition, because MKs have an important role in the pathogenesis of acute megakaryocytic leukaemia and a subset of myeloproliferative neoplasms, including essential thrombocythemia and primary myelofibrosis, we discuss the biology and genetics of these disorders. We anticipate that an increased understanding of normal MK differentiation will provide new insights into novel therapeutic approaches that will directly benefit patients.
AB - Megakaryopoiesis is the process by which bone marrow progenitor cells develop into mature megakaryocytes (MKs), which in turn produce platelets required for normal haemostasis. Over the past decade, molecular mechanisms that contribute to MK development and differentiation have begun to be elucidated. In this review, we provide an overview of megakaryopoiesis and summarise the latest developments in this field. Specially, we focus on polyploidisation, a unique form of the cell cycle that allows MKs to increase their DNA content, and the genes that regulate this process. In addition, because MKs have an important role in the pathogenesis of acute megakaryocytic leukaemia and a subset of myeloproliferative neoplasms, including essential thrombocythemia and primary myelofibrosis, we discuss the biology and genetics of these disorders. We anticipate that an increased understanding of normal MK differentiation will provide new insights into novel therapeutic approaches that will directly benefit patients.
UR - http://www.scopus.com/inward/record.url?scp=84857080157&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84857080157&partnerID=8YFLogxK
U2 - 10.1017/s1462399411002043
DO - 10.1017/s1462399411002043
M3 - Review article
C2 - 22018018
AN - SCOPUS:84857080157
SN - 1462-3994
VL - 13
SP - e32
JO - Expert reviews in molecular medicine
JF - Expert reviews in molecular medicine
ER -